Novartis considers selling its $5B+ ophthalmology and respiratory units — report
As Novartis has been focusing its core pipeline, and spinning off its generics arm Sandoz, the company may be looking to sell even more.
According to a report from Bloomberg today, the Swiss pharma is considering the sale of some of its “non-core” assets to raise funds to invest in “cutting-edge medicines,” people familiar with the matter said.
The report elaborates that Novartis is in the early phases of “considering options” for its respiratory and ophthalmology units, which wouldn’t close until after Sandoz spins out, with anonymous sources telling the publication that private equity firms could spend up to $5 billion on the ophthalmology unit alone, according to Bloomberg.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.